Trials / Completed
CompletedNCT00546637
Fesoterodine "add-on" Male Overactive Bladder Study
A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Fesoterodine As An "Add-On" Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of Alpha Blocker For Lower Urinary Tract Symptoms.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 947 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fesoterodine | Fesoterodine 4mg or 8mg |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2007-10-19
- Last updated
- 2011-02-18
- Results posted
- 2010-11-22
Locations
137 sites across 19 countries: United States, Belgium, Brazil, Canada, Colombia, Germany, Greece, India, Malaysia, Netherlands, Norway, Philippines, Poland, Singapore, Slovakia, South Korea, Spain, Sweden, Thailand
Source: ClinicalTrials.gov record NCT00546637. Inclusion in this directory is not an endorsement.